{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:04:24Z","timestamp":1784541864393,"version":"3.55.0"},"reference-count":59,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15716","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:43:26Z","timestamp":1781865806000},"page":"1-11","source":"Crossref","is-referenced-by-count":0,"title":["Application and challenges of chimeric antigen receptor T cell therapy in the treatment of acute myeloid leukemia (Review)"],"prefix":"10.3892","volume":"32","author":[{"given":"Jingjing","family":"Zhang","sequence":"first","affiliation":[{"name":"First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi 341001, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feilin","family":"Wang","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi 341001, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Sui","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi 341001, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Huang","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi 341001, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Gannan Medical University, Jiangxi Provincial Clinical Research Center for Endemic Diseases (Thalassemia), Ganzhou, Jiangxi 341001, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"key20260720122129_b1-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.15537\/smj.2024.45.10.20240330","article-title":"CAR T-cell therapy in acute myeloid leukemia","volume":"45","author":"Almotiri","year":"2024","journal-title":"Saudi Med J"},{"key":"key20260720122129_b2-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2023022481","article-title":"How I treat refractory and relapsed acute myeloid leukemia","volume":"143","author":"Thol","year":"2024","journal-title":"Blood"},{"key":"key20260720122129_b3-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"e18369","DOI":"10.1111\/jcmm.18369","article-title":"Recent advances in CAR-T cell therapy for acute myeloid leukaemia","volume":"28","author":"Gao","year":"2024","journal-title":"J Cell Mol Med"},{"key":"key20260720122129_b4-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00005-023-00684-x","article-title":"Updated clinical perspectives and challenges of chimeric antigen receptor-T cell therapy in colorectal cancer and invasive breast cancer","volume":"71","author":"Cao","year":"2023","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"key20260720122129_b5-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3390\/biomedicines12061194","article-title":"CAR-T cells in acute myeloid leukemia: Where do we stand?","volume":"12","author":"Damiani","year":"2024","journal-title":"Biomedicines"},{"key":"key20260720122129_b6-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1182\/blood.2023022922","article-title":"The present and future of CAR T-cell therapy for adult B-cell ALL","volume":"145","author":"Short","year":"2025","journal-title":"Blood"},{"key":"key20260720122129_b7-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"11505","DOI":"10.1074\/jbc.274.17.11505","article-title":"The Myeloid-Specific Sialic Acid-binding Receptor, CD33, Associates with the Protein-tyrosine Phosphatases, SHP-1 and SHP-2*","volume":"274","author":"Taylor","year":"1999","journal-title":"J Biol Chem"},{"key":"key20260720122129_b8-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/ijc.33865","article-title":"CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells","volume":"150","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"key":"key20260720122129_b9-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"20406207231154708","DOI":"10.1177\/20406207231154708","article-title":"Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia","volume":"14","author":"Swaminathan","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"key20260720122129_b10-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","article-title":"Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: Preclinical evaluation and phase I trial","volume":"14","author":"Huang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"key20260720122129_b11-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1021\/acssynbio.3c00320","article-title":"Conditional control of universal CAR T cells by cleavable off-switch adaptors","volume":"12","author":"Kvorjak","year":"2023","journal-title":"ACS Synth Biol"},{"key":"key20260720122129_b12-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"S369","DOI":"10.1182\/blood-2024-211517","article-title":"Autologous CD33CART for children and adolescents\/young adults with relapsed\/refractory AML: Phase 1\/2 clinical trial correlative biology analyses demonstrate potent in vitro, in vivo, and ex vivo anti-leukemia activity","volume":"144","author":"Balestra","year":"2024","journal-title":"Blood"},{"key":"key20260720122129_b13-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"S3467","DOI":"10.1182\/blood-2024-207659","article-title":"The safety and efficacy of CD33 CAR-T therapy for RR AML after HSCT","volume":"144","author":"Lin","year":"2024","journal-title":"Blood"},{"key":"key20260720122129_b14-ol-32-2-15716","first-page":"965","article-title":"Target selection for CAR-T therapy in acute myeloid leukemia-review","volume":"32","author":"Shao","year":"2024","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"key20260720122129_b15-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","article-title":"Unveiling the potential of CLL-1: A promising target for AML therapy","volume":"13","author":"Soleimani Samarkhazan","year":"2025","journal-title":"Biomarker Res"},{"key":"key20260720122129_b16-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"6643948","DOI":"10.1155\/2021\/6643948","article-title":"C-type lectin-like molecule-1 as a biomarker for diagnosis and prognosis in acute myeloid leukemia: A preliminary study","volume":"2021","author":"Wang","year":"2021","journal-title":"Biomed Res Int"},{"key":"key20260720122129_b17-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J Hematol Oncol"},{"key":"key20260720122129_b18-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","article-title":"Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: The multi-center efficacy and safety interim analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"key20260720122129_b19-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s12967-022-03797-7","article-title":"Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R\/R-AML)","volume":"20","author":"Lu","year":"2022","journal-title":"J Transl Med"},{"key":"key20260720122129_b20-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s12185-021-03182-y","article-title":"Prognostic value of lymphoid marker CD7 expression in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in first morphological complete remission","volume":"114","author":"Lv","year":"2021","journal-title":"Int J Hematol"},{"key":"key20260720122129_b21-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ymthe.2018.10.001","article-title":"CD7 CAR T cells for the therapy of acute myeloid leukemia","volume":"27","author":"Gomes-Silva","year":"2019","journal-title":"Mol Ther"},{"key":"key20260720122129_b22-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","article-title":"Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies","volume":"31","author":"Watanabe","year":"2023","journal-title":"Mol Ther"},{"key":"key20260720122129_b23-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: A phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"key":"key20260720122129_b24-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.3390\/ijms24032718","article-title":"CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm","volume":"24","author":"Pelosi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20260720122129_b25-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","article-title":"Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis","volume":"100","author":"Testa","year":"2002","journal-title":"Blood"},{"key":"key20260720122129_b26-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1200\/JCO.21.01595","article-title":"CD123 expression is associated with high-risk disease characteristics in childhood acute myeloid leukemia: A report from the children's oncology group","volume":"40","author":"Lamble","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20260720122129_b27-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s12185-019-02616-y","article-title":"Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia","volume":"109","author":"Arai","year":"2019","journal-title":"Int J Hematol"},{"key":"key20260720122129_b28-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"2275457","DOI":"10.1080\/21645515.2023.2275457","article-title":"Building safety into CAR-T therapy","volume":"19","author":"Peters","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"key20260720122129_b29-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"S4584","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML: Preliminary results from a phase 1 trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"key":"key20260720122129_b30-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3390\/cancers14051164","article-title":"Role of biomarkers in FLT3 AML","volume":"14","author":"Nitika","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20260720122129_b31-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.3390\/jcm12206429","article-title":"A Review of FLT3 kinase inhibitors in AML","volume":"12","author":"Negotei","year":"2023","journal-title":"J Clin Med"},{"key":"key20260720122129_b32-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"key":"key20260720122129_b33-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-024-01617-7","article-title":"Quizartinib: A potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML","volume":"17","author":"Cortes","year":"2024","journal-title":"J Hematol Oncol"},{"key":"key20260720122129_b34-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/ejh.14103","article-title":"Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma","volume":"112","author":"Cai","year":"2024","journal-title":"Eur J Haematol"},{"key":"key20260720122129_b35-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1053\/j.seminhematol.2025.08.003","article-title":"The immunotherapy landscape in AML: Defining knowledge gaps toward rational combinatorial strategies","volume":"62","author":"Subklewe","year":"2025","journal-title":"Semin Hematol"},{"key":"key20260720122129_b36-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J"},{"key":"key20260720122129_b37-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1182\/blood-2005-03-1072","article-title":"Hematopoietic stem cells express multiple myeloid markers: Implications for the origin and targeted therapy of acute myeloid leukemia","volume":"106","author":"Taussig","year":"2005","journal-title":"Blood"},{"key":"key20260720122129_b38-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"key20260720122129_b39-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12929-022-00866-3","article-title":"Tumor microenvironment: Barrier or opportunity towards effective cancer therapy","volume":"29","author":"Tiwari","year":"2022","journal-title":"J Biomed Sci"},{"key":"key20260720122129_b40-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1182\/bloodadvances.2025017011","article-title":"International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML","volume":"9","author":"Naik","year":"2025","journal-title":"Blood Adv"},{"key":"key20260720122129_b41-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities","volume":"19","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"key20260720122129_b42-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"e159839","DOI":"10.1172\/JCI159839","article-title":"Hypoxia-inducible factors: Cancer progression and clinical translation","volume":"132","author":"Wicks","year":"2022","journal-title":"J Clin Invest"},{"key":"key20260720122129_b43-ol-32-2-15716","first-page":"58","article-title":"CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities","volume":"28","author":"Khanolkar","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"key20260720122129_b44-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.trecan.2016.10.016","article-title":"Hypoxia-inducible factors: Master regulators of cancer progression","volume":"2","author":"Schito","year":"2016","journal-title":"Trends Cancer"},{"key":"key20260720122129_b45-ol-32-2-15716","first-page":"1442","article-title":"Mechanism and preclinical evaluation of cytokine release syndrome induced by monoclonal antibodies","volume":"33","author":"Fu","year":"2024","journal-title":"Chin J New Drugs"},{"key":"key20260720122129_b46-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"100751","DOI":"10.1016\/j.omto.2023.100751","article-title":"Bispecific CD33\/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia","volume":"31","author":"Boucher","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"key20260720122129_b47-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00262-024-03847-7","article-title":"Loop33 \u00d7 123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia","volume":"74","author":"Ma","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"key20260720122129_b48-ol-32-2-15716","first-page":"127","article-title":"Bispecific CD33\/CD123 targeted chimeric antigen receptor T cells for improved selective preclinical treatment of acute myeloid leukemia","volume":"38","author":"Hossain","year":"2024","journal-title":"Leukemia"},{"key":"key20260720122129_b49-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"101695","DOI":"10.1016\/j.tranon.2023.101695","article-title":"Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape","volume":"34","author":"Xie","year":"2023","journal-title":"Transl Oncol"},{"key":"key20260720122129_b50-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ejh.14104","article-title":"Tandem bispecific CD123\/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia","volume":"112","author":"Wang","year":"2024","journal-title":"Eur J Haematol"},{"key":"key20260720122129_b51-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"101250","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape-lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"key20260720122129_b52-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"1401683","DOI":"10.3389\/fimmu.2024.1401683","article-title":"Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR\/Cas9 editing and safety evaluation of the transcriptome","volume":"15","author":"Pavlovic","year":"2024","journal-title":"Front Immunol"},{"key":"key20260720122129_b53-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/cells13020146","article-title":"Allogeneic CAR-T therapy technologies: has the promise been met?","volume":"13","author":"Lonez","year":"2024","journal-title":"Cells"},{"key":"key20260720122129_b54-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"102147","DOI":"10.1016\/j.tranon.2024.102147","article-title":"Universal CAR cell therapy: Challenges and expanding applications","volume":"51","author":"Wu","year":"2025","journal-title":"Transl Oncol"},{"key":"key20260720122129_b55-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"1465191","DOI":"10.3389\/fimmu.2024.1465191","article-title":"Application of novel CAR technologies to improve treatment of autoimmune disease","volume":"15","author":"Cheever","year":"2024","journal-title":"Front Immunol"},{"key":"key20260720122129_b56-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"S751","DOI":"10.1182\/blood-2023-187418","article-title":"And-gate CAR T-cells to improve tumour specificity and targeting of low-expression antigens in multiple myeloma","volume":"142","author":"Anderson","year":"2023","journal-title":"Blood"},{"key":"key20260720122129_b57-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"1490911","DOI":"10.3389\/fimmu.2024.1490911","article-title":"Logic-gated and contextual control of immunotherapy for solid tumors: Contrasting multi-specific T cell engagers and CAR-T cell therapies","volume":"15","author":"Nolan-Stevaux","year":"2024","journal-title":"Front Immunol"},{"key":"key20260720122129_b58-ol-32-2-15716","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T cell tumor recognition: Tuned antigen sensing and logic gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov"},{"key":"key20260720122129_b59-ol-32-2-15716","first-page":"103489","article-title":"Accelerating CAR T cell manufacturing with an automated next-day process","volume":"73","author":"Ahmadi","year":"2025","journal-title":"Curr Res Transl Med"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:21:35Z","timestamp":1784539295000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,19]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15716","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]}}}